The European Alliance of Associations for Rheumatology - held its 2026 annual Congress in London, where gout was high on the ...

Read new insights in urate-lowering therapy in a treat-to-target strategy for gout management, heard at EULAR 2026.

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

Sobi announces positive topline results from pivotal phase 3 REDUCE 2 study of pozdeutinurad in gout: Stockholm, Sweden Saturday, May 23, 2026, 11:00 Hrs [IST] Sobi, a global biop ...

Topline results from the phase 3 REDUCE 2 trial show that investigational pozdeutinurad effectively lowers serum uric acid in adults with gout.

Sobi® (STO: SOBI) today announced positive topline results from the pivotal Phase 3 REDUCE 2 study (NCT06439602) evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral ...

The chronic gout market is experiencing significant growth driven by rising prevalence due to aging populations and lifestyle changes, notably obesity and urbanization. Improved clinical guidelines ...

Crystalys Therapeutics has dosed the first patient with its once daily oral, URAT1 inhibitor dotinurad in its Phase II AMETHYST trial (NCT07535034), designed to assess dotinurad’s effectiveness in ...

Both doses of once-daily pozdeutinurad (AR882) met the primary efficacy endpoint of sUA reduction at month 6 vs placebo Pozdeutinurad was overall well tolerated, and the safety profile was consistent ...

Source: Getty Images Gout and chronic kidney disease frequently co-occur with important clinical implications. Uncontrolled gout can increase the risk for new-onset or worsening chronic kidney disease ...

Gout is a true crystal deposition disease caused by the formation of monosodium urate crystals in and around joints. 1 Crystal formation occurs when tissues become supersaturated with urate and local ...

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or ...